Merus N.V.

Merus N.V. is an oncology company based in The Netherlands, founded in 2003. It is focused on developing Biclonics® bispecific antibody therapeutics aimed at treating and potentially curing cancer patients. The company's most advanced development programs utilize the innovative Biclonics® format, which enables simultaneous attacks on tumors in multiple ways, such as activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways. Merus offers a thriving environment for career growth and development, providing opportunities for both individual and company success. The company emphasizes making a meaningful impact within the oncology field by contributing to the development of bispecific antibody therapies (Biclonics®) to combat cancer. With headquarters in The Netherlands and offices in the US, as well as collaborators worldwide, Merus has established itself as a prominent player in the biotechnology and healthcare industries. In 2016, Merus was listed on NASDAQ, and over the course of 10 years, it has initiated several candidate drugs in clinical trials, showcasing its commitment to advancing innovative therapies. The company's recent milestone includes a $400.20M Post-IPO Equity investment on 29 May 2024. For more information, please visit www.merus.nl.